189 related articles for article (PubMed ID: 38029491)
21. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
[TBL] [Abstract][Full Text] [Related]
22. Bloodstream infections in neutropenic cancer patients: A practical update.
Gustinetti G; Mikulska M
Virulence; 2016 Apr; 7(3):280-97. PubMed ID: 27002635
[TBL] [Abstract][Full Text] [Related]
23. An eleven-year cohort of bloodstream infections in 552 febrile neutropenic patients: resistance profiles of Gram-negative bacteria as a predictor of mortality.
Kara Ali R; Surme S; Balkan II; Salihoglu A; Sahin Ozdemir M; Ozdemir Y; Mete B; Can G; Ar MC; Tabak F; Saltoglu N
Ann Hematol; 2020 Aug; 99(8):1925-1932. PubMed ID: 32564194
[TBL] [Abstract][Full Text] [Related]
24. Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to Pseudomonas aeruginosa in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH Study).
Bergas A; Albasanz-Puig A; Fernández-Cruz A; Machado M; Novo A; van Duin D; Garcia-Vidal C; Hakki M; Ruiz-Camps I; Del Pozo JL; Oltolini C; DeVoe C; Drgona L; Gasch O; Mikulska M; Martín-Dávila P; Peghin M; Vázquez L; Laporte-Amargós J; Durà-Miralles X; Pallarès N; González-Barca E; Álvarez-Uría A; Puerta-Alcalde P; Aguilar-Company J; Carmona-Torre F; Clerici TD; Doernberg SB; Petrikova L; Capilla S; Magnasco L; Fortún J; Castaldo N; Carratalà J; Gudiol C
Microbiol Spectr; 2022 Jun; 10(3):e0229221. PubMed ID: 35475683
[TBL] [Abstract][Full Text] [Related]
25. Bloodstream infection in cancer patients; susceptibility profiles of the isolated pathogens, at Khartoum Oncology Hospital, Sudan.
Zain OM; Elsayed MY; Abdelkhalig SM; Abdelaziz M; Ibrahim SY; Bashir T; Hamadalnil Y
Afr Health Sci; 2022 Dec; 22(4):70-76. PubMed ID: 37092093
[TBL] [Abstract][Full Text] [Related]
26. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
[TBL] [Abstract][Full Text] [Related]
27. Is current initial empirical antibiotherapy appropriate to treat bloodstream infections in short-duration chemo-induced febrile neutropenia?
Joncour A; Puyade M; Michaud A; Tourani JM; Cazenave-Roblot F; Rammaert B
Support Care Cancer; 2020 Jul; 28(7):3103-3111. PubMed ID: 31667604
[TBL] [Abstract][Full Text] [Related]
28. Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit.
Cordero L; Rau R; Taylor D; Ayers LW
Am J Infect Control; 2004 Jun; 32(4):189-95. PubMed ID: 15175611
[TBL] [Abstract][Full Text] [Related]
29. Bloodstream infections and antibiotic resistance patterns: a six-year surveillance study from southern Italy.
Foglia F; Della Rocca MT; Melardo C; Nastri BM; Manfredini M; Montella F; De Filippis A; Finamore E; Galdiero M
Pathog Glob Health; 2023 Jun; 117(4):381-391. PubMed ID: 36190133
[TBL] [Abstract][Full Text] [Related]
30. Study of Common Bacterial and Fungal Pathogens in Children with Hematological Malignancies during Febrile Neutropenia: Single Center Egyptian Study.
Hagag AA; Hassan SM; Elgamasy MA; Afifi IK
Infect Disord Drug Targets; 2016; 16(1):54-62. PubMed ID: 26715443
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital.
Poon LM; Jin J; Chee YL; Ding Y; Lee YM; Chng WJ; Chai LY; Tan LK; Hsu LY
Singapore Med J; 2012 Nov; 53(11):720-5. PubMed ID: 23192498
[TBL] [Abstract][Full Text] [Related]
32. Frequency of microbial isolates and pattern of antimicrobial resistance in patients with hematological malignancies: a cross-sectional study from Palestine.
Arman G; Zeyad M; Qindah B; Abu Taha A; Amer R; Abutaha S; Koni AA; Zyoud SH
BMC Infect Dis; 2022 Feb; 22(1):146. PubMed ID: 35144553
[TBL] [Abstract][Full Text] [Related]
33. Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India.
Ghosh S; Chakraborty M; Samanta S; Sinha N; Saha S; Chattopadhyay A; Roy SS; Bhattacharyya M
Ann Hematol; 2021 Feb; 100(2):395-403. PubMed ID: 33140134
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology, Risk Factors, and Clinical Outcomes of Bloodstream Infection due to Extended-Spectrum Beta-Lactamase-Producing
Liang T; Xu C; Cheng Q; Tang Y; Zeng H; Li X
Microb Drug Resist; 2021 Jun; 27(6):800-808. PubMed ID: 33232654
[No Abstract] [Full Text] [Related]
35. Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant Gram-negative organisms.
Nouér SA; Nucci M; Anaissie E
Expert Rev Hematol; 2015 Oct; 8(5):647-58. PubMed ID: 26115679
[TBL] [Abstract][Full Text] [Related]
36. [Single Center Analysis of Bloodstream Infection Clinical Characteristics and Prognosis in Patients with Hematological Malignancies in the Tropics].
Cheng LC; Yang T; Kuang HH; Yu S; Guan LX; Gu ZY; Xu YY; Zheng WS; Wang L; Hu YL; Gao XN; Wang QS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):265-271. PubMed ID: 33554832
[TBL] [Abstract][Full Text] [Related]
37. Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
Cumpston A; Craig M; Hamadani M; Abraham J; Hobbs GR; Sarwari AR
Transpl Infect Dis; 2013 Apr; 15(2):142-9. PubMed ID: 23279656
[TBL] [Abstract][Full Text] [Related]
38. Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study.
Okamoto A; Kanda Y; Kimura SI; Oyake T; Tamura K;
Int J Hematol; 2021 Oct; 114(4):472-482. PubMed ID: 34170481
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and Outcomes of Carbapenem-resistant Bloodstream Infection in Children With Cancer.
Nirmal G; Jithin TK; Gopakumar KG; Parthiban R; Nair C
J Pediatr Hematol Oncol; 2023 Aug; 45(6):e678-e682. PubMed ID: 37146155
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia.
Castagnola E; Caviglia I; Pescetto L; Bagnasco F; Haupt R; Bandettini R
Future Microbiol; 2015; 10(3):357-64. PubMed ID: 25812459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
